These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. The utility of TTF-1, napsin A, CK5 and p63 staining in the sub-classification of non-small cell carcinoma of the lung. van Zyl A; Schubert PT; Koegelenberg CFN Cytopathology; 2019 Nov; 30(6):586-591. PubMed ID: 31206846 [TBL] [Abstract][Full Text] [Related]
65. The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. Conde E; Angulo B; Izquierdo E; Muñoz L; Suárez-Gauthier A; Plaza C; Dominguez N; Torres M; Madrigal L; Rubio-Viqueira B; Belda-Iniesta C; Hidalgo M; López-Ríos F Histopathology; 2013 Mar; 62(4):609-16. PubMed ID: 23379755 [TBL] [Abstract][Full Text] [Related]
66. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507 [TBL] [Abstract][Full Text] [Related]
67. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: A tissue microarray study of poorly differentiated areas. Noh S; Shim H Lung Cancer; 2012 Apr; 76(1):51-5. PubMed ID: 21978426 [TBL] [Abstract][Full Text] [Related]
68. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
69. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma. Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741 [TBL] [Abstract][Full Text] [Related]
70. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Jain D; Nambirajan A; Chen G; Geisinger K; Hiroshima K; Layfield L; Minami Y; Moreira AL; Motoi N; Papotti M; Rekhtman N; Russell PA; Prince SS; Schmitt F; Yatabe Y; Eppenberger-Castori S; Bubendorf L; J Thorac Oncol; 2022 Jun; 17(6):793-805. PubMed ID: 35331963 [TBL] [Abstract][Full Text] [Related]
71. [Feasibility of assessing EGFR mutation and others using samples obtained by EBUS transbronchial needle aspiration]. Boulanger S; Delattre C; Descarpentries C; Escande F; Bouchindhomme B; Copin MC; Dhalluin X; Scherpereel A; Ramon PP; Cortot A; Fournier C Rev Mal Respir; 2013 May; 30(5):351-6. PubMed ID: 23746811 [TBL] [Abstract][Full Text] [Related]
72. A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations. Riely GJ; Johnson ML; Medina C; Rizvi NA; Miller VA; Kris MG; Pietanza MC; Azzoli CG; Krug LM; Pao W; Ginsberg MS J Thorac Oncol; 2011 Aug; 6(8):1435-7. PubMed ID: 21847063 [TBL] [Abstract][Full Text] [Related]
73. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633 [TBL] [Abstract][Full Text] [Related]
74. [Molecular pathology of lung cancer: key to personalized medicine]. Cheng L; Li Y; Zhang SB; Teng XD Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321 [No Abstract] [Full Text] [Related]
75. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843 [TBL] [Abstract][Full Text] [Related]